目的 觀察并分析黃芪注射液聯(lián)合更昔洛韋對小兒巨細胞病毒性肝炎的臨床療效。方法 選取南陽市第二人民醫(yī)院2013年1月-2017年6月收治的小兒巨細胞病毒性肝炎患者44例，按照治療方法分成對照組、觀察組，各22例。對照組進行更昔洛韋治療，觀察組在對照組的基礎(chǔ)上進行黃芪注射液治療，兩組均治療4周。比較兩組臨床療效的總有效率、血清CMV-IgM轉(zhuǎn)陰率、不良反應(yīng)發(fā)生率。結(jié)果 觀察組的臨床療效總有效率是86.36%，顯著高于對照組的63.63%，差異有統(tǒng)計學(xué)意義（P<0.05）。觀察組血清CMV-IgM轉(zhuǎn)陰率是81.82%，顯著高于對照組的40.91%，差異有統(tǒng)計學(xué)意義（P<0.05）。觀察組患兒的不良反應(yīng)發(fā)生率是13.64%，明顯低于對照組的54.55%，差異有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 黃芪注射液聯(lián)合更昔洛韋對小兒巨細胞病毒性肝炎的療效好，安全、可靠，值得臨床應(yīng)用和推廣。

Objective To observe and analyze the clinical efficacy of astragalus injection combined with ganciclovir in children with cytomegalovirus hepatitis. Methods Selected 44 patients with cytomegalovirus hepatitis in our hospital from January 2013 to June 2017. All patients were divided into the control group and observation group by treatment methods, each group of 22 cases. The control group was treated with ganciclovir. The observation group was treated with astragalus injection on the basis of the control group. The total effective rate of clinical efficacy, serum CMV-IgM negative rate and the incidence of adverse reactions were compared between the two groups. Results The total effective rate of clinical efficacy of the observation group (86.36%) was significantly higher than that of the control group (63.63%) (P<0.05). The serum CMV-IgM negative rate of observation group (81.82%) was significantly higher than that in the control group (40.91%) (P<0.05). The incidence of adverse events in the observation group (13.64%) was significantly lower than that in the control group (54.55%) (P<0.05). Conclusions The clinical efficacy of astragalus injection combined with ganciclovir in children with cytomegalovirus hepatitis is fine, safe and reliable, worthy of clinical application and promotion.